PedAM
Pediatric Disease Annotations & Medicines
| Disease | c syndrome |
| Phenotype | |hypertension |
| Sentences | 140 |
| PubMedID- 22829804 | hypertension is another component of the metabolic syndrome which is independently associated with increased cardiovascular risk. |
| PubMedID- 21107432 | The prevalence of metabolic syndrome (mets) in patients with essential hypertension is very high, and has been estimated as being close to 50%.1 hypertensive patients with mets have a much higher cardiovascular (cv) risk than their counterparts without mets,2 and also have a particularly high risk of developing type 2 diabetes mellitus (t2dm).3 in addition, the choice of antihypertensive therapy can have a large impact on the risk of development of t2dm.4 renin–angiotensin system blockers, that is, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (arbs), improve insulin sensitivity and reduce the risk of developing t2dm compared with placebo, whereas calcium channel blockers (ccbs) have a neutral effect. |
| PubMedID- 25916862 | Renin-angiotensin-aldosterone system (raas) inhibition with an ace or an arb and treatment with calcium channel blockers appears safe and well tolerated in obesity-related hypertension and in patients with metabolic syndrome. |
| PubMedID- 23318820 | Introduction: the treatment of arterial hypertension (ah) in patients with metabolic syndrome (ms) is a challenge, since non drug therapies are difficult to implement and optimal pharmacological treatment is not fully established. |
| PubMedID- 20176994 | Obese persons with metabolic syndrome often have associated with salt-sensitive hypertension, microalbuminuria, and cardiac dysfunction, and the plasma aldosterone level in one-third of metabolic syndrome patients is clearly elevated. |
| PubMedID- 25999772 | Previous literature has also hypothesized that white coat hypertension is associated with metabolic syndrome.25 metabolic syndrome is defined as an elevated risk for cardiovascular disease and diabetes. |
| PubMedID- 22350229 | Obesity, dyslipidemia, type 2 diabetes, hypertension, and other components of metabolic syndrome actively correlate with development of nonalcoholic fatty liver disease (nafld) and hepatic insulin resistance and inadequate diabetes resolution after rygb [26]. |
| PubMedID- 25306760 | [arterial hypertension in metabolic syndrome: pathophysiological aspects]. |
| PubMedID- 21516767 | [pathogenetic aspects of arterial hypertension in metabolic syndrome]. |
| PubMedID- 25354240 | Thus, preserved stimulation of proximal tubule transport through the insulin/irs2/pi3-k pathway may play an important role in the pathogenesis of hypertension associated with metabolic syndrome. |
| PubMedID- 20016031 | Although recent evidence underscores the role of heme-oxygenase (ho) in diabetes, its effects on insulin sensitivity and glucose metabolism in spontaneously hypertensive rat (shr), a model of essential hypertension with characteristics of metabolic syndrome including insulin resistance/impaired glucose metabolism remains largely unclear. |
| PubMedID- 22305998 | A subgroup analysis in patients with hypertension and comorbidities of diabetes, cardiometabolic syndrome, or obesity, and in black participants is reported. |
| PubMedID- 22555437 | Comprehensive studies, ranging from in vitro, in vivo, preclinical, to human, all suggest that attenuation of gc signaling, through 11β-hsd1 inhibition in metabolically important tissue such as the liver, is a therapeutically achievable strategy to ameliorate the glucose intolerance, obesity, fatty liver, and hypertension associated with metabolic syndrome. |
| PubMedID- 22294071 | Exploratory studies in patients with resistant hypertension and a variety of comorbidities, including insulin resistance/metabolic syndrome, obstructive sleep apnea and the polycystic ovary syndrome, have shown benefit of renal denervation in attenuating the severity of the comorbid conditions, as well as reducing bp. |
| PubMedID- 25758604 | Impaired right ventricular hemodynamics indicate preclinical pulmonary hypertension in patients with metabolic syndrome. |
| PubMedID- 24417059 | Clinical features of arterial hypertension in patients with metabolic syndrome are described with reference to antihypertensive therapy and the choice of adequate drugs for the purpose. |
| PubMedID- 20877591 | It should only rarely be done in patients with intractable pain, bleeding, uncontrolled hypertension, symptoms due to paraneoplastic syndromes such as uncontrolled hypercalcemia, erythrocytosis, if usual measures fail. |
| PubMedID- 22940679 | Objective: nonalcoholic fatty liver and hypertension are associated with metabolic syndrome. |
| PubMedID- 20213371 | In addition, in refractory hypertension and in patients with metabolic syndrome aldosterone seems to play an important role. |
| PubMedID- 24583433 | Gemcitabine induces hemolytic uremic syndrome with accelerated hypertension and raynaud's phenomenon, mimicking scleroderma renal crisis. |
| PubMedID- 26064845 | In fact, insulin resistance, dyslipidemia, obesity and hypertension, each of these variables of metabolic syndrome gets influenced by the serum uric acid level. |
| PubMedID- 25659889 | Peripheral insulin resistance is a key component of metabolic syndrome associated with obesity, dyslipidemia, hypertension, and type 2 diabetes. |
| PubMedID- 23511769 | Middle aortic syndrome as the cause of renovascular hypertension in a 3-year-old girl: difficulties in the differential diagnosis. |
| PubMedID- 22691241 | Logistic regression (backward selection) was further performed to calculate odds ratios (ors) for high versus low homa-ir according to demographic and lifestyle (gender, age, tobacco use), metabolic (obesity, hypertension, use of statins, metabolic syndrome), and clinical parameters, including the das28, health assessment questionnaire (haq), crp, and ra treatment modality (glucocorticoids, methotrexate). |
| PubMedID- 20798846 | In large cohorts, ghrelin is higher in women than men [70] and declines with age, body mass index (bmi), hypertension, and other markers of the metabolic syndrome [70]. |
| PubMedID- 24658007 | Hsd11b1 enzymatic activities are thought to be involved in obesity, hypertension, and other components of the metabolic syndrome. |
| PubMedID- 23365487 | In particular, tnf expression, which was shown to be increased in response to pressure overload in the adult heart [75], might be one of the most important mediators of cardiac hypertrophy in metabolic syndrome with hypertension [76]. |
| PubMedID- 22934054 | On the other hand, increased adipose tissue mass is associated with insulin resistance, systemic dyslipidemia, hyperglycemia, hypertension, and components of the metabolic syndrome (dandona et al., 2005; despres, 2006). |
| PubMedID- 26447765 | hypertension, one diagnostic criterion of metabolic syndrome, is regulated by the renin-angiotensin system [8] and angiotensin ii (angii) is important as a target of antihypertensive drugs. |
| PubMedID- 22293193 | Salt-sensitive hypertension is a characteristic of the metabolic syndrome. |
| PubMedID- 23517220 | Abpm should be a priority for persons likely to have a blunted nighttime bp decline and elevated cvd risk, i.e., those who are elderly and obese, those with secondary or resistant hypertension, and those diagnosed with diabetes, ckd, metabolic syndrome, and sleep disorders. |
| PubMedID- 25508240 | Material and methods: we conducted an 8-week open prospective study on 36 patients with essential stage ii hypertension associated with metabolic syndrome. |
| PubMedID- 24441717 | Although a wide range of potentially therapeutic effect of asiatic acid have been reported, little is known about the effect of asiatic acid on metabolic syndrome associated with hypertension in diet-induced ms. the aim of the present study was to investigate whether asiatic acid can improve metabolic and cardiovascular complications in an animal model of hchf diet-induced metabolic syndrome. |
| PubMedID- 21623724 | [possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes]. |
| PubMedID- 21143427 | Dietary fructose, salt absorption and hypertension in metabolic syndrome: towards a new paradigm. |
| PubMedID- 24122442 | Pm should be a priority for personslikely to have a blunted nighttime bp decline and elevated cvd risk, i.e., those who are elderly and obese, those with secondary or resistant hypertension, andthose diagnosed with diabetes, ckd, metabolic syndrome, and sleep disorders.de vigo, vigo, pontevedra, espana. |
| PubMedID- 24798707 | Metabolic syndrome induces hypertension and commonly results in renal damage. |
| PubMedID- 21925996 | The renin-angiotensin system (ras) is a common link between hypertension and comorbidities of obesity and metabolic syndrome (mets). |
| PubMedID- 21155616 | Background and objective: metabolic syndrome is common in patients with hypertension and increases the risk of developing diabetes mellitus. |
| PubMedID- 23837008 | A subgroup analysis was done to evaluate the effects in high-risk black participants with stage 2 hypertension and comorbidities of diabetes, cardiometabolic syndrome, or obesity.77 at the end of the study, blood pressure was reduced to goal in 75.4% of triple therapy-treated participants with diabetes compared with 55.8% of dual therapy-treated participants, 69.6% of triple therapy-treated participants with cardiometabolic syndrome compared with 50.7% of dual therapy-treated participants, and 68.4% of triple therapy-treated participants with obesity compared with 49.6% of dual therapy-treated participants. |
| PubMedID- 23641349 | hypertension, another aspect of the metabolic syndrome, might also be a component contributing to neuropathy, although not much is known about the mechanism. |
| PubMedID- 20383279 | Whereas arbs and acei have demonstrated their efficiency in improving insulin sensitivity and reducing end-organ damage and are now often considered as first-line therapy in hypertension with metabolic syndrome or diabetes [3], [4], [5], [30], association of anti-oxidants or anti-nitrants in an attempt to further reduce deleterious nitrative stress might be worth considering in severely affected or non-responsive patients. |
| PubMedID- 23340319 | Dyslipidemia and glucose intolerance are, apart from hypertension and obesity, constituents of the so-called metabolic syndrome and of non-insulin-dependent diabetes mellitus. |
| PubMedID- 20609696 | These agents may expand the utility of beta-blockers to patient populations traditionally considered not to be optimal candidates for beta-blocker therapy-a fact which has important clinical implications, because more antihypertensive agents are needed to diversify the therapeutic options available for clinicians treating hypertension in patients with the cardiometabolic syndrome or type 2 diabetes. |
| PubMedID- 26504474 | Increased fructose ingestion has been linked to obesity, hyperglycemia, dyslipidemia, and hypertension associated with metabolic syndrome. |
| PubMedID- 20368993 | Our findings now suggest that seasonal weight gain bridges npas2 and hypertension to the pathogenesis of the metabolic syndrome. |
| PubMedID- 22190906 | Vascular endothelial dysfunction has been demonstrated in metabolic syndrome with and without hypertension or diabetes [1–3]. |
| PubMedID- 20972515 | Urbanisation is associated with obesity, hypertension and development of the metabolic syndrome (ms). |
| PubMedID- 24474950 | Sixty-six self-identified african-american subjects with stage 1 and 2 hypertension and characteristics of the cardiometabolic syndrome were treated with amlodipine/olmesartan (a/o) versus losartan/hydrochlorothiazide (l/h) for 20 weeks in an open-label, active comparator fashion. |
| PubMedID- 22304322 | [features of treatment of hypertension in patients with metabolic syndrome]. |